Haemonetics Corporation

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 21:00:02 28/06/2024 BST			5-day change	1st Jan Change
82.73 ^USD	-0.54%		-2.89%	-3.25%

06-18	Haemonetics Corporation Launches Limited Market Release of its New VASCADE MVP XL Mid-Bore Venous Closure Device	CI
06-12	Haemonetics Shares Rise After Upgrade From Needham	MT

Haemonetics Corporation Announces the Resignation of Brian Burns as Executive Vice President, Global Quality and Regulatory Affairs

January 11, 2016 at 09:42 pm

Haemonetics Corporation announced that on January 11, 2016, Brian Burns resigned as Executive Vice President, Global Quality and Regulatory Affairs to pursue other opportunities.

Latest news about Haemonetics Corporation

Haemonetics Corporation Launches Limited Market Release of its New VASCADE MVP XL Mid-Bore Venous Closure Device	06-18	CI
Haemonetics Shares Rise After Upgrade From Needham	06-12	MT
Needham Upgrades Haemonetics to Buy From Hold, Sets Price Target at $112	06-12	MT
Haemonetics Insider Sold Shares Worth $1,144,208, According to a Recent SEC Filing	05-29	MT
Haemonetics Insider Sold Shares Worth $775,253, According to a Recent SEC Filing	05-29	MT
Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes	05-23	MT
Haemonetics Insider Sold Shares Worth $254,443, According to a Recent SEC Filing	05-21	MT
Haemonetics Plans Notes Offering	05-21	MT
Tranche Update on Haemonetics Corporation's Equity Buyback Plan announced on August 10, 2022.	05-20	CI
Barrington Research Raises Price Target on Haemonetics to $107 From $105, Keeps Outperform Rating	05-10	MT
Haemonetics Seeks Acquisitions	05-09	CI
Transcript : Haemonetics Corporation, Q4 2024 Earnings Call, May 09, 2024	05-09
Haemonetics' Fiscal Q4 Adjusted Earnings, Revenue Rise	05-09	MT
Haemonetics Corporation Reports Earnings Results for the Full Year Ended March 30, 2024	05-09	CI
Haemonetics Corporation Reports Earnings Results for the Fourth Quarter Ended March 30, 2024	05-09	CI
Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2025	05-09	CI
Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge	04-04	MT
Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge	04-04	CI
Haemonetics Corporation completed the acquisition of Advanced Cooling Therapy, Inc.	03-31	CI
Haemonetics to Acquire Attune Medical for $160 Million	03-05	MT
Haemonetics Corporation entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc. for approximately $160 million.	03-04	CI
Haemonetics Q3 Adjusted Earnings, Revenue Increase; Shares Rise	02-08	MT
Transcript : Haemonetics Corporation, Q3 2024 Earnings Call, Feb 08, 2024	02-08
North American Morning Briefing : S&P 500 to Open -2-	02-08	DJ
Tranche Update on Haemonetics Corporation's Equity Buyback Plan announced on August 10, 2022.	02-08	CI

Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Companyâs Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment includes blood collection and processing devices and disposables for red cells, platelets and whole blood. The Companyâs Hospital segment consists of Interventional Technologies, which includes vascular closure devices and sensor-guided technologies, and Blood Management Technologies, which includes devices and methodologies for measuring coagulation characteristics of blood, and blood transfusion management software, among others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

25/07/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Haemonetics Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

82.73 USD

Average target price

113.3 USD

Spread / Average Target

+36.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
HAEMONETICS CORPORATION	-3.25%	4.22B
ABBOTT LABORATORIES	-5.60%	181B
MEDTRONIC PLC	-4.45%	101B
BECTON, DICKINSON AND COMPANY	-4.15%	67.54B
DEXCOM, INC.	-8.63%	45.09B
CENCORA, INC.	+9.70%	44.37B
HOYA CORPORATION	+5.36%	40.7B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.22%	29.85B
TERUMO CORPORATION	+10.26%	24.49B
WEST PHARMACEUTICAL SERVICES, INC.	-6.46%	23.99B

Other Medical Equipment, Supplies & Distribution